NCT06441669

Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT

Effect of Letermovir Prophylaxis on Cytomegalovirus-specific Immune Reconstitution Post Unrelated Cord Blood Transplantation

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 60 (estimated)
• Sponsor: Anhui Provincial Hospital · Other Government
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

To explore the effect of letermovir prophylaxis on cytomegalovirus-specific immune reconstitution post unrelated cord blood transplantation

Detailed description

To explore the effect of letermovir prophylaxis on cytomegalovirus-specific and other lymphocyte subsets immune reconstitution post unrelated cord blood transplantation, and to analyze the potential mechanism and risk factors of late CMV reactivation after letermovir discontinuation.

Conditions

• Cytomegalovirus Infection Reactivation

Interventions

Type	Name	Description
DRUG	Letermovir	Patients will be given Letermovir with a recommended dose from +1 day to +100 days after UCBT.

Timeline

• Start date: 2024-05-01
• Primary completion: 2026-05-01
• Completion: 2026-05-20
• First posted: 2024-06-04
• Last updated: 2024-06-04

Locations

1 site across 1 country: China